Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market, By Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia, and Others), Product and Service (Kits, Software, and Services and Instruments), Technologies (Panels/Targeted Sequencing and Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing, and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis, and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics, and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2030.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Analysis and Size
Next-generation sequencing (NGS) has brought huge developments in personalized medicine for oncology. Next-generation technology allows time and cost-effective sequencing of cancerous DNA, transforming research on cancer treatment. The market is expected to be impacted considerably by improvements in personalized medicine and oncology. NGS deployment in a clinical setting provides several intriguing possibilities. Thus, all these are significantly impacting the market growth.
Data Bridge Market Research analyses a growth rate in the next generation sequencing (NGS) in cancer diagnostic market in the forecast period 2023-2030. The expected CAGR of next generation sequencing (NGS) in the cancer diagnostic market is around 15.6% in the mentioned forecast period. The market was valued at USD 684.99 million in 2022, and it would grow up to USD 2184.50 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Lung, Breast, Colorectal, Prostrate, Stomach, Cervical, Leukemia, and Others), Product and Service (Kits, Software, and Services and Instruments), Technologies (Panels/Targeted Sequencing and Resequencing, Whole Exome Sequencing, Whole Genome Sequencing, RNA Sequencing, and Other Sequencing Technologies), Workflow (NGS Sequencing, NGS Data Analysis, and NGS Pre-Sequencing), Application (Screening, Companion Diagnostics, and Others), End User (Pathology Labs, Hospitals, Oncology Centers and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Illumina, Inc. (U.S.), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies Inc. (U.S.), Myriad Genetics Inc. (U.S.), BGI (China), Perkin Elmer Inc. (U.S.), Foundation Medicine Inc. (U.S.), PacBio (U.S.), Oxford Nanopore Technologies plc. (U.K.), Paradigm Diagnostics Inc. (U.S.), Caris Life Sciences (Japan), Partek, Incorporated (U.S.), Eurofins Scientific (Luxembourg), QIAGEN (Germany)
|
|
Market Opportunities
|
|
Market Definition
Next-generation sequencing or NGS, is also known as high-throughput sequencing. It is a technology that utilizes extreme parallelization to gather enormous DNA strands. The innovation reduces the requirement for segment cloning, a step in Sanger genome sequencing. NGS also creates precision medicine for treating patients with varied illnesses.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Dynamics
Drivers
- Growing Use in Agri-Genomics Research and Increasing Healthcare Expenditure
Several plants and animals use NGS as a genomic tool, which is expected to increase the market's expansion. In India's GDP for the year 2018, agriculture was a close second to mining at 17%. Rice, sugarcane, and eucalyptus are new examples of current applications of NGS to extract genetic variation for crop improvement. Large populations of specimens can be screened promptly by NSG. Several new plant species can be domesticated instantly with the growing application of NSG, which also helps to identify and collect novel genetic variation from closely associated species. Thus, this factor boosts market growth.
Opportunities
- Increasing Application in Precision Oncology
The increase in clinical applications of next-generation sequencing in precision oncology has boosted the efforts of the major market players to develop novel platforms that can be used widely for genomic assays. For instance, Congenica collaborated with Gabriel Precision Oncology Ltd. to manufacture an automatic clinical oncology interpretation software platform. Thus, this factor boosts market growth.
- Rising Demand for Targeted Cancer Sequencing Panels
Increasing demand for targeted cancer sequencing panels is extensively increasing the market's growth. Targeted cancer sequencing panels help decrease the time, cost, and amount of data analyzed while sequencing tumor samples. Furthermore, the increasing efficiency of targeted panels to identify malignant tumors improves their clinical utility. As per a study published in JCO Precision Oncology, 2020, NGS panels are clinically useful in 64% of cancer cases. Thus, this factor increases the growth of the market.
Restraints/Challenges
- High Cost of Genomic Technology
High cost, along with technology, is a major hindrance to the market's growth during the forecast period. High costs associated with poor outsourced service efficiency, installation of different sequencing platforms, and little availability of sequencing platforms are all expected to limit the development of next-generation sequencing in the cancer diagnostic market. All these factors hamper the growth of the market.
This next generation sequencing (NGS) in cancer diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the next generation sequencing (NGS) in cancer diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Burning Rock Biotech Limited, a China-based cancer test provider, entered into a partnership with Illumina to promote the standardization and development of NGS-based cancer therapy selection within China. The company also signed an agreement with Myriad Genetics, Inc. to develop and commercialize myChoice tumor testing in China.
Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Scope
The next generation sequencing (NGS) in cancer diagnostic market is segmented on the basis of cancer type, product and service, technologies, workflow, application, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Lung
- Breast
- Colorectal
- Prostrate
- Stomach
- Cervical
- Leukemia
- Others
Product and Service
- Kits
- Software and Services
- Instruments
Technologies
- Panels/Targeted Sequencing and Resequencing
- Whole Exome Sequencing
- Whole Genome Sequencing
- RNA Sequencing
- Other Sequencing Technologies
Workflow
- NGS Sequencing
- NGS Data Analysis
- NGS Pre-Sequencing
Application
- Screening
- Companion Diagnostics
- Others
End User
- Pathology Labs
- Hospitals
- Oncology Centers
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Next Generation Sequencing (NGS) in Cancer Diagnostic Market Regional Analysis/Insights
The next generation sequencing (NGS) in cancer diagnostic market is analyzed and market size insights and trends are provided by cancer type, product and service, technologies, workflow, application, distribution channel and end-user as referenced above.
The major countries covered in the next generation sequencing (NGS) in cancer diagnostic market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
China is expected to have the highest growth rate in the forecast period because of the technological advancements in molecular biology. It has improved the sequencing methods, which is anticipated to improve the market growth. The major players in the country provide NGS products and services at a highly competitive price than the other countries
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Next Generation Sequencing (NGS) in Cancer Diagnostic Market Share Analysis
The next generation sequencing (NGS) in cancer diagnostic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to next generation sequencing (NGS) in cancer diagnostic market
Key players operating in the next generation sequencing (NGS) in cancer diagnostic market include:
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies Inc. (U.S.)
- Myriad Genetics Inc. (U.S.)
- BGI (China), Perkin Elmer Inc. (U.S.)
- Foundation Medicine Inc. (U.S.)
- PacBio (U.S.)
- Oxford Nanopore Technologies plc. (U.K.)
- Paradigm Diagnostics Inc. (U.S.)
- Caris Life Sciences (Japan)
- Partek, Incorporated (U.S.)
- Eurofins Scientific (Luxembourg)
- QIAGEN (Germany)
SKU-